Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Next Previous
Trial Profile

Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Hydrocortisone; Mercaptopurine; Methotrexate; Mitoxantrone; Pegaspargase; Vincristine
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen; Onyx Pharmaceuticals

Most Recent Events

  • 24 Sep 2024 This trial has been completed in Austria (Global end date: 2024-06-28) according to European Clinical Trials Database record.
  • 20 Sep 2024 This trial has been completed in Greece (Global end date: 2024-06-28) according to European Clinical Trials Database record.
  • 15 Aug 2024 This trial has been discontinued in Denmark (Global end date: 28 June 2024).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top